[SCHEDULE 13G/A] Biohaven Ltd. Amended Passive Investment Disclosure
Janus Henderson Group plc reported beneficial ownership of 11.7% of Biohaven Ltd. through its Asset Managers. These Asset Managers collectively hold 17,534,612 common shares and exercise shared voting and dispositive power on behalf of various Managed Portfolios. The filing clarifies that no single Managed Portfolio owns more than 5% of Biohaven Ltd.
Biohaven (BHVN) Narrows Loss and Adds Shelf Registration Is Its Capital Strategy Evolving?
Biohaven (BHVN) recently reported a narrowed net loss in Q1 2026 and filed an omnibus shelf registration, potentially signaling an evolving capital strategy. The shelf registration offers flexibility for future fundraising through various securities, which is crucial given the company's limited cash runway and significant stock price depreciation. While Biohaven's clinical pipeline remains a key investment narrative, investors are watching for how future financing might impact dilution and shareholder value.
Biohaven (BHVN) Narrows Loss and Adds Shelf Registration Is Its Capital Strategy Evolving?
Biohaven Ltd. reported a narrowed net loss of US$130.53 million in Q1 2026 and lower loss per share. Concurrently, the company filed an omnibus shelf registration, providing flexibility for future capital raises. This move is significant given less than a year of cash runway and a recent 43% drop in share price, highlighting evolving strategies to fund its pipeline and manage potential dilution.
Morgan Stanley Cuts Price Target on Biohaven to $18 From $21, Keeps Overweight Rating
Morgan Stanley has lowered its price target for Biohaven Pharmaceuticals (NYSE:BHVN) to $18 from $21, while maintaining an Overweight rating on the stock. This adjustment reflects a revised valuation perspective by the firm.
Biohaven Ltd. Stock 12‑Month Price Target Cut to $22.19, Implies 141% Upside
Biohaven Ltd.'s average 12-month price target has been adjusted to $22.19, down slightly from $22.47, according to 16 analysts. This new target suggests a potential upside of approximately 141% based on the May 12 closing price. The consensus rating for Biohaven Ltd. remains "Buy," with 12 analysts recommending Buy and 5 recommending Hold.
Biohaven (BHVN) Valuation Check After Q1 Results And New Shelf Registration
Biohaven (BHVN) is under scrutiny after its Q1 results and a new shelf registration. Despite a reduced net loss, its share price has fallen significantly, leading to questions about its valuation. The company's Price-to-Book ratio of 10.6x is below peers but well above the biotech sector, indicating that its current market value relies heavily on expectations for its extensive pipeline rather than current profitability.
H.C. Wainwright reiterates Biohaven stock rating ahead of trial
H.C. Wainwright has reiterated a Neutral rating and $10.00 price target for Biohaven Pharma (BHVN) due to uncertainty surrounding its pipeline, as the stock has declined 56% over the past year. The firm remains cautious ahead of the upcoming second-half 2026 pivotal readout for opakalim in FOS, a key catalyst. Biohaven faces increased pressure for clinical success as it is burning through cash, and competitors' recent successes in similar mechanisms raise the bar for efficacy and tolerability differentiation.
How Biohaven Ltd. (BHVN) Affects Rotational Strategy Timing
This article analyzes Biohaven Ltd. (BHVN) using AI models, highlighting weak sentiment across all time horizons and suggesting a significant short-bias opportunity. It details distinct trading strategies—position, momentum breakout, and risk hedging—with specific entry, target, and stop-loss levels, while also providing multi-timeframe signal analysis for support and resistance levels. The report emphasizes the exceptional 84.7:1 risk-reward short setup for BHVN.
Biohaven Ltd. (BHVN) upgraded to buy: Here's why
This article announces that Biohaven Ltd. (BHVN) has received an analyst upgrade from "hold" to "buy" by Truist. The upgrade is based on the company's strong management team, early success with its new migraine drug Zavegepant, and the potential for a pipeline of other neuroscience-focused drugs. Truist raised its price target for BHVN to $50, suggesting significant upside potential.
Biohaven Warns of Broad Operational, Financial and Market Risks, Affirms Overall Risk Profile Matches Prior 10-K Disclosures
Biohaven Ltd. (BHVN) has issued a new risk disclosure concerning broad operational, financial, and market events that could negatively impact its financial standing and stock price. The company asserts that its overall risk profile remains consistent with previous disclosures in its Form 10-K filed on March 2, 2026. Despite these warnings, Wall Street maintains a Moderate Buy consensus rating for BHVN stock.
Biohaven (BHVN) Is Up 5.7% After Narrower Q1 Loss And Pivotal Trial Plans – Has The Bull Case Changed?
Biohaven Ltd. (BHVN) reported a narrower Q1 2026 loss of US$130.53 million, an improvement from the previous year, and announced plans to begin pivotal trials for its MoDE and TRAP protein degradation platform and other late-stage programs in 2026. This progress strengthens the company's pipeline and investment narrative, although significant risks remain regarding clinical setbacks, funding, and a rich valuation. Retail investor estimates for fair value vary widely, reflecting the complex and high-risk nature of Biohaven's R&D-focused business model.
Biohaven (NYSE: BHVN) adds $350.0 million at-the-market share program
Biohaven Ltd. has entered into an amended Equity Distribution Agreement with J.P. Morgan Securities LLC, establishing an "at-the-market" equity offering program. This program allows Biohaven to sell up to $350.0 million in common shares starting May 4, 2026, through J.P. Morgan. The sales will occur on the New York Stock Exchange or through negotiated transactions, with the timing and volume depending on the company's capital needs and prevailing market conditions.
Biohaven (BHVN) Is Up 5.7% After Narrower Q1 Loss And Pivotal Trial Plans – Has The Bull Case Changed?
Biohaven Ltd. reported a narrower Q1 2026 net loss of US$130.53 million, down from US$221.68 million year-over-year, and announced plans for pivotal trials in Graves’ disease and IgA nephropathy later in 2026. Despite a 5.7% stock increase post-announcement, the company faces significant risks including funding needs with less than a year of cash, clinical setbacks, and valuation concerns after a 55.17% share price decline over the last year. The investment narrative heavily relies on the success of its broad, high-risk pipeline to justify ongoing losses without revenue.
Biohaven (BHVN) Is Up 5.7% After Narrower Q1 Loss And Pivotal Trial Plans – Has The Bull Case Changed?
Biohaven Ltd. reported a narrower Q1 2026 net loss of US$130.53 million and announced plans for pivotal trials for its MoDE and TRAP protein degradation platform, as well as other late-stage programs in 2026. The company's investment narrative focuses on its high-risk pipeline, zero revenue, and ongoing losses, with significant risks including clinical setbacks, funding needs, and a rich valuation.
Biohaven (NYSE: BHVN) trims Q1 2026 loss and raises $178.9M
Biohaven Ltd. (NYSE: BHVN) reported a narrowed net loss of $130.5 million in Q1 2026, down from $221.7 million in Q1 2025, primarily due to significantly reduced research and development and general and administrative expenses. The company bolstered its financial position by issuing common shares through an at-the-market equity program, raising $178.9 million, and maintaining $273.1 million in cash and cash equivalents, which is expected to fund operations for at least one year. Biohaven is focusing its resources on three late-stage clinical programs: Kv7 ion channel modulation for epilepsy, MoDE/TRAP extracellular protein degraders for immunological diseases, and a myostatin-activin pathway targeting agent for neuromuscular and metabolic diseases.
Biohaven Pharma (BHVN) files mixed shelf
Biohaven Pharma (BHVN) has filed a mixed shelf offering that includes common shares, preferred shares, depositary shares, debt securities, warrants, rights, purchase contracts, and units. The stock is currently priced at $10.14, up 5.30%, with an overall analyst rating of SELL. This filing provides the company with flexibility to raise capital through various securities in the future.
Biohaven Ltd files for mixed shelf offering size not disclosed - SEC filing
Biohaven Ltd. has filed for a mixed shelf offering, according to an SEC filing. The size of this offering has not been disclosed. This news comes shortly after the company reported its Q1 adjusted loss per share and completed enrollment for its Phase 2 obesity study.
Earnings Flash (BHVN) Biohaven Ltd. Posts Q1 Adjusted Loss $0.69 per Share, Vs. FactSet Est of $-0.83
Biohaven Ltd. (BHVN) announced its Q1 adjusted loss per share was $0.69, which is better than the FactSet estimate of a $0.83 loss. This financial update indicates the company's performance relative to analyst expectations for the first quarter.
Biohaven (NYSE: BHVN) cuts Q1 2026 loss while funding late-stage drug pipeline
Biohaven Ltd. reported significantly narrowed losses in Q1 2026, with net loss decreasing to $130.5 million from $221.7 million year-over-year, alongside a strengthened balance sheet. The company is advancing multiple late-stage drug programs, including pivotal trials for epilepsy and planned initiations for Graves’ disease and IgA nephropathy, with key data readouts expected in the second half of 2026. This financial improvement is attributed to disciplined cost management and program reprioritization while maintaining a robust clinical pipeline supported by $351.8 million in cash and equivalents.
Biohaven (NYSE: BHVN) shareholders back directors, auditors and pay plan
Biohaven Ltd. shareholders recently approved key proposals during their 2026 annual meeting. They voted to re-elect three directors—Michael T. Heffernan, Irina Antonijevic, M.D., Ph.D., and Robert J. Hugin—and ratified Ernst & Young LLP as the independent auditors for the fiscal year ending December 31, 2026. Additionally, shareholders passed a non-binding advisory vote concerning the compensation of the company’s named executive officers.
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
Biohaven Ltd. reported its first quarter 2026 financial results, highlighting a "transformative year ahead" with multiple milestones. The company is advancing several pipeline programs, including pivotal trials for its extracellular protein degradation platform (BHV-1300 and BHV-1400) and expected topline results for its epilepsy and obesity programs in the second half of 2026. Biohaven also reported a reduced net loss of $130.5 million for Q1 2026 compared to $221.7 million in Q1 2025, primarily due to decreases in R&D and general administrative expenses.
Biohaven Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026
Biohaven Ltd. reported a net loss of USD 130.53 million for the first quarter ended March 31, 2026, a decrease from USD 221.68 million in the same period last year. The basic and diluted loss per share from continuing operations was USD 0.88, significantly improved from USD 2.17 a year ago. The company, a clinical-stage biopharmaceutical firm, is focused on developing treatments in immunology, neuroscience, and oncology.
Assessing Biohaven (BHVN) Valuation After Prolonged Share Price Weakness And Elevated P/B Ratio
Biohaven (BHVN) has experienced significant share price weakness, with an 18% decline in three months and a nearly 58% drop over the past year, despite progress in its drug pipeline. The company's valuation shows a high Price-to-Book (P/B) ratio of 27.8x, which is considerably above its peer group and the broader US biotech industry averages. This elevated P/B ratio is noted alongside Biohaven's lack of revenue, substantial net loss, negative return on equity, and limited cash runway, raising concerns about its valuation being overstretched.
Assessing Biohaven (BHVN) Valuation After Prolonged Share Price Weakness And Elevated P/B Ratio
Biohaven (BHVN) has experienced significant share price weakness, with an 18% decline in the past 3 months and a 57.86% drop over the last year. Despite a low share price of US$9.63 compared to an analyst target of US$22.24, the company trades at a high Price-to-Book multiple of 27.8x, indicating it is overvalued relative to its peers and the biotech industry, especially given its lack of revenue and substantial net losses. The high P/B ratio reflects investor willingness to pay for future pipeline potential, but serious risks remain due to its loss-making status, cash constraints, and reliance on high-risk funding.
68,693 Biohaven (BHVN) options granted to board director
Biohaven Ltd. director Michael Thomas Heffernan was granted 68,693 stock options on April 28, 2026, with an exercise price of $9.61 per share and an expiration date of April 28, 2036. These compensation-related options vest in full on the earlier of April 28, 2027, or the date of Biohaven's 2027 Annual Meeting of Shareholders, provided Heffernan continues his service. This transaction increases his direct holdings to 68,693 options and is not an open-market purchase or sale.
Biohaven Faces Catalyst-Rich 2H 2026 With Multiple Key Readouts Ahead
Biohaven Ltd. (BHVN) is poised for a significant second half of 2026, with critical data readouts expected to influence the future of its diverse pipeline. The biopharmaceutical company is focusing on novel MoDE and TRAP platforms, which are designed to target the underlying causes of autoimmune diseases by selectively removing disease-causing proteins. The article indicates that further details are available to premium subscribers.
Biohaven (BHVN) director awarded 68,693 options vesting in 2027
Biohaven Ltd. director Irina Antonijevic was granted 68,693 stock options with an exercise price of $9.61 per share. These options will vest in full on the earlier of April 28, 2027, or the 2027 Annual Meeting of Shareholders, provided her continuous service. The options expire on April 28, 2036, representing equity-based compensation rather than a market transaction.
Director Julia P. Gregory awarded 68,693 Biohaven (BHVN) stock options
Biohaven Ltd. director Julia P. Gregory was granted 68,693 stock options to purchase Common Shares at an exercise price of $9.61 per share, as compensation. These options will fully vest on the earlier of April 28, 2027, or the date of Biohaven’s 2027 Annual Meeting of Shareholders, provided her continuous service to the company. After this award, she directly holds 68,693 stock options that expire on April 28, 2036.
Director at Biohaven (NYSE: BHVN) receives 68,693 stock options award
Biohaven Ltd. director John W. Childs was granted 68,693 stock options with an exercise price of $9.61 per share, expiring on April 28, 2036. This compensation award vests on the earlier of April 28, 2027 or the 2027 Annual Meeting of Shareholders, contingent on his continuous service. Following this transaction, Childs directly holds 68,693 stock options in Biohaven (BHVN).
(BHVN) and the Role of Price-Sensitive Allocations
This article provides an AI-generated analysis for Biohaven Ltd. (NASDAQ: BHVN), highlighting weak near-term sentiment and a significant risk-reward setup. It outlines three institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles, along with multi-timeframe signal analysis indicating support and resistance levels. The analysis emphasizes real-time signals, risk management, and the use of AI models for predictive insights.
Biohaven (NYSE:BHVN) Trading Up 5.2% - Here's What Happened
Biohaven (NYSE:BHVN) saw its stock price increase by 5.2% on Tuesday, closing at $10.0880, though this surge occurred on light trading volume. Analysts currently have a "Moderate Buy" consensus rating for the company with a target price of $22.53, despite some mixed ratings ranging from "Strong Buy" to "Strong Sell." Biohaven, a clinical-stage biopharmaceutical company focused on neurological and neurovascular diseases, reported an EPS of -$1.21 last quarter, beating estimates by $0.01.
Biohaven Obesity Trial Milestone Puts Focus On Taldefgrobep And Valuation Gap
Biohaven has completed enrollment for its Phase 2 proof-of-concept trial for the obesity drug candidate taldefgrobep alfa, with topline results expected later this year. This milestone adds a new focus area for investors, alongside the company's neurology pipeline, given the strong interest in the obesity market. Despite recent stock volatility, the current price is significantly below analyst targets, though Simply Wall St's independent valuation status is unknown.
Biohaven Obesity Trial Milestone Puts Focus On Taldefgrobep And Valuation Gap
Biohaven Ltd. has completed enrollment for its Phase 2 trial of taldefgrobep alfa, an obesity drug candidate, with topline results expected later this year. This development brings a new focus to the company beyond its neurology pipeline, as the stock has experienced recent volatility. The market will be watching the trial's performance, especially given the current lack of independent fair value assessment and the company's reported losses and potential for dilution.
BHVN SEC Filings - Biohaven 10-K, 10-Q, 8-K Forms
This page provides access to Biohaven Ltd. (BHVN) SEC filings, including 10-K, 10-Q, and 8-K reports, with AI-powered summaries. Recent filings detail the FDA's PDUFA extension for troriluzole, changes to the Knopp Biosciences acquisition agreement reducing milestone payments, and Biohaven's Q2 2025 financial results showing continued operating loss and new secured notes. The platform aims to offer detailed insights into the company's regulatory disclosures and financial status.
Assessing Biohaven (BHVN) Valuation After Sharp One Month Rebound And Steep One Year Decline
Biohaven (BHVN) has seen a significant valuation rebound in the last month, despite a steep decline over the past year. The company, which is currently loss-making and has a high Price-to-Book ratio of 30.9x, suggests investor confidence is primarily in its future pipeline and potential clinical milestones. This premium valuation is noted to be substantially higher than industry averages and carries risks due to its zero revenue base and net loss.
Assessing Biohaven (BHVN) Valuation After Sharp One Month Rebound And Steep One Year Decline
Biohaven (BHVN) has seen a significant one-month price rebound of 22.2% following a substantial 50.1% decline over the past year. Despite this recent momentum, the company is still loss-making with a high Price-to-Book ratio of 30.9x, significantly above industry averages, suggesting investors are placing a high premium on its future potential rather than current financials. The article advises investors to review underlying data and warning signs due to the mixed performance and valuation.
Moderate Buy Rating Seen For Biohaven Ltd. (BHVN)
Biohaven Ltd. (BHVN) has received a moderate buy rating from analysts with an average price target of $21.44, despite a significant decline in its stock price over the last year. The company recently completed enrollment for a Phase 2 study of taldefgrobep alfa, a potential treatment for obesity, with topline data expected in the second half of the year. Biohaven is a biopharmaceutical company focusing on various therapeutic areas, including immunology, obesity, neuroscience, and oncology.
Moderate Buy Rating Seen For Biohaven Ltd. (BHVN)
Biohaven Ltd. (BHVN) has received a "moderate buy" rating from analysts with an average price target of $21.44, despite a recent stock decline. The company recently completed enrollment for a Phase 2 study of taldefgrobep alfa, a myostatin-activin pathway inhibitor aiming to achieve high-quality weight loss in obesity, with topline data expected in the second half of the year. Biohaven is a biopharmaceutical company focused on various therapeutic areas, including obesity, and is advancing its innovative pipeline.
Biohaven (NYSE:BHVN) Shares Down 5.7% - What's Next?
Biohaven (NYSE:BHVN) shares dropped 5.7% with exceptionally low trading volume. Despite analyst consensus being a "Moderate Buy" with an average price target of $22.53, and the company slightly beating Q4 EPS estimates, institutional investors have significantly increased their stakes, now owning nearly 89% of the company. Biohaven is a clinical-stage biopharmaceutical company focused on neurological and neurovascular diseases, with its primary program centered on migraine treatments.
Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating
Canaccord Genuity initiated coverage of Biohaven Ltd. (BHVN) with a Buy rating and a $21 price target, citing the company's development of novel therapeutics and the potential upside from its opakalim epilepsy readout. Citi also reiterated its Buy rating, raising its price target to $17 and highlighting attractive risk/reward ahead of 2026 catalysts. The firms believe Biohaven, a clinical-stage biopharmaceutical company, is undervalued, particularly given its focal epilepsy program.
Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating
Canaccord initiated coverage of Biohaven Ltd. (BHVN) with a Buy rating and a $21 price target, citing the company's novel therapeutics development and the undervaluation based on its opakalim opportunity. Citi also raised its price target to $17 from $14, maintaining a Buy rating due to attractive risk/reward and positive implications from competitor data for Biohaven's Phase 3 opakalim trial. Biohaven is a clinical-stage biopharmaceutical company focused on neurological and neuropsychiatric diseases.
Responsive Playbooks and the BHVN Inflection
The article provides an AI-driven analysis of Biohaven Ltd. (NASDAQ: BHVN), highlighting strong near and mid-term sentiment but a weak long-term outlook. It identifies a mid-channel oscillation pattern and an exceptional short setup for BHVN, targeting a 23.8% downside with minimal risk. The analysis also details three institutional trading strategies tailored to different risk profiles.
Why Biohaven (BHVN) Is Up 10.6% After Bullish Analyst Coverage Of Late-Stage Pipeline Prospects
Biohaven's stock rose 10.6% following bullish analyst coverage of its late-stage clinical pipeline, particularly its Phase 3 opakalim program for focal epilepsy and a Phase 2 obesity study. Despite having no revenue and significant annual losses, positive interpretation of competitor data and upcoming trial readouts in late 2026 have shifted investor sentiment, though the company still faces high risk, a cash burn, and legal uncertainties.
Why Biohaven (BHVN) Is Up 10.6% After Bullish Analyst Coverage Of Late-Stage Pipeline Prospects
Biohaven's stock rose 10.6% following renewed bullish analyst coverage on its late-stage clinical pipeline, including the opakalim program for focal epilepsy and the taldefgrobep alfa obesity study. While this positive attention highlights upcoming trial readouts as key catalysts, the company still faces significant financial challenges with no revenue and considerable annual losses, suggesting a high-risk investment profile. Investors are urged to consider varied viewpoints and the potential for further funding needs despite the recent shift in sentiment.
Why Biohaven (BHVN) Is Up 10.6% After Bullish Analyst Coverage Of Late-Stage Pipeline Prospects
Biohaven (BHVN) saw a 10.6% stock jump following positive analyst coverage of its late-stage clinical pipeline, including the Phase 3 opakalim program for epilepsy and a Phase 2 obesity study. Analysts view competitor drug data as supportive for Biohaven's programs, intensifying focus on upcoming trial readouts in the second half of 2026. Despite the bullish sentiment and stock increase, Biohaven remains a high-risk biotech with no revenue, significant losses, and potential for further funding needs, prompting a recommendation for investors to consider various viewpoints and risks.
Biohaven Ltd. (NYSE:BHVN) Given Consensus Rating of "Moderate Buy" by Analysts
Eighteen analysts have assigned Biohaven Ltd. (NYSE:BHVN) a "Moderate Buy" consensus rating, with an average 1-year price target of $22.53. The company's shares opened at $10.35, and while it reported a negative P/E ratio, its Q1 EPS of ($1.21) beat expectations. Analyst price targets vary, reflecting mixed expectations for the biopharmaceutical company focused on neurological and neurovascular diseases.
Biohaven Receives 'Moderate Buy' Rating from Analysts
Biohaven Ltd. (NYSE:BHVN) has received an average 'Moderate Buy' rating from eighteen research firms, with an average 12-month price target of $22.53. This target represents a potential upside of over 100% from its current trading price of around $10.35. The biopharmaceutical company focuses on therapies for neurological and neurovascular diseases, and analysts show cautious optimism for its future prospects.
Why Institutions Are Turning Bullish on Biohaven—and the Catalyst That Could Unlock Its Value
Biohaven Ltd. (BHVN) is experiencing a shift in investor sentiment, with institutions turning bullish despite past setbacks. This renewed interest is driven by a "Buy" rating from Canaccord Genuity, an activist stake by Sarissa Capital Management, and upcoming clinical trial readouts for its epilepsy drug opakalim and an obesity candidate. The company, now with a streamlined pipeline and a solid cash position, is viewed as a "reset" story with significant potential if clinical milestones are met.
CCORF Initiates Biohaven(BHVN.US) With Buy Rating, Announces Target Price $21
CCORF has initiated coverage on Biohaven (BHVN.US) with a Buy rating. The firm has set a target price of $21 for the company's stock. This indicates a positive outlook on Biohaven's future performance.
Here is why Biohaven (BHVN) is Among the Top Healthcare Stocks Insiders Are Buying
Biohaven Ltd. (NYSE:BHVN) is presented as a top healthcare stock that insiders are buying, with recent analyst price target increases and maintained Buy ratings. The company has several catalysts expected in the second half of 2026, including Phase 3 data for opakalim in focal epilepsy and Phase 2 data for taldefgrobep alfa for weight loss. Goldman Sachs also raised its price target, citing supportive data from a competitor for the broader Kv7 class, which includes Biohaven’s opakalim.
